Tarsus Pharmaceuticals (NASDAQ:TARS) Stock Price Expected to Rise, Oppenheimer Analyst Says

Tarsus Pharmaceuticals (NASDAQ:TARS) had its price target upped by stock analysts at Oppenheimer from $95.00 to $105.00 in a report released on Wednesday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Oppenheimer’s price target indicates a potential upside of 38.39% from the company’s previous close.

Several other research firms have also recently weighed in on TARS. Mizuho started coverage on Tarsus Pharmaceuticals in a research note on Thursday, November 20th. They set an “outperform” rating and a $100.00 target price for the company. Wall Street Zen raised shares of Tarsus Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. Guggenheim upped their target price on shares of Tarsus Pharmaceuticals from $87.00 to $90.00 and gave the company a “buy” rating in a report on Wednesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research report on Thursday, January 22nd. Finally, Barclays started coverage on shares of Tarsus Pharmaceuticals in a research report on Monday, December 8th. They issued an “overweight” rating and a $100.00 price target for the company. Two equities research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $87.00.

Tarsus Pharmaceuticals Stock Performance

Shares of TARS stock opened at $75.87 on Wednesday. The company has a market cap of $3.23 billion, a P/E ratio of -46.83, a PEG ratio of 1.05 and a beta of 0.57. The firm has a fifty day moving average price of $72.12 and a 200 day moving average price of $68.43. The company has a current ratio of 3.85, a quick ratio of 4.25 and a debt-to-equity ratio of 0.21. Tarsus Pharmaceuticals has a 12 month low of $38.51 and a 12 month high of $85.25.

Tarsus Pharmaceuticals (NASDAQ:TARS) last posted its quarterly earnings results on Monday, February 23rd. The company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). The business had revenue of $151.67 million during the quarter, compared to analyst estimates of $144.56 million. Tarsus Pharmaceuticals had a negative net margin of 14.72% and a negative return on equity of 19.63%. Sell-side analysts predict that Tarsus Pharmaceuticals will post -3.17 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Dianne C. Whitfield sold 7,397 shares of the business’s stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $80.10, for a total value of $592,499.70. Following the transaction, the insider owned 38,958 shares in the company, valued at $3,120,535.80. The trade was a 15.96% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Bobak R. Azamian sold 6,000 shares of the company’s stock in a transaction that occurred on Wednesday, December 24th. The shares were sold at an average price of $82.51, for a total value of $495,060.00. Following the sale, the chief executive officer directly owned 857,991 shares of the company’s stock, valued at approximately $70,792,837.41. This represents a 0.69% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 8.97% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of TARS. Comerica Bank raised its stake in shares of Tarsus Pharmaceuticals by 470.0% during the fourth quarter. Comerica Bank now owns 855 shares of the company’s stock worth $70,000 after purchasing an additional 705 shares during the last quarter. Truvestments Capital LLC increased its stake in Tarsus Pharmaceuticals by 106.1% in the 4th quarter. Truvestments Capital LLC now owns 909 shares of the company’s stock valued at $74,000 after buying an additional 468 shares during the period. Leonteq Securities AG purchased a new position in Tarsus Pharmaceuticals during the 4th quarter worth $164,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Tarsus Pharmaceuticals by 26.4% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,063 shares of the company’s stock worth $169,000 after acquiring an additional 431 shares during the period. Finally, Mackenzie Financial Corp purchased a new stake in shares of Tarsus Pharmaceuticals in the fourth quarter valued at about $202,000. 90.01% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Tarsus Pharmaceuticals

Here are the key news stories impacting Tarsus Pharmaceuticals this week:

• Positive Sentiment: Oppenheimer raised its price target materially and reiterated a positive stance (Outperform), which supports upside expectations for the shares. Oppenheimer Raises PT
• Positive Sentiment: Guggenheim raised its price target on TARS to $90 and maintained a Buy rating, providing additional analyst-level backing for further gains. Guggenheim PT $90
• Positive Sentiment: Tarsus announced management will participate in upcoming investor conferences—this increases management access to investors and can help sustain the re-rating momentum if management delivers encouraging updates. Investor Conferences
• Neutral Sentiment: A market commentary questioned whether Tarsus has been re-rated too cautiously following XDEMVY adoption headlines; this article frames debate about valuation vs execution but does not add hard fundamentals. Market Rerate Analysis
• Negative Sentiment: HC Wainwright trimmed multiple near-term and multi-year EPS forecasts in its Feb. 24 research note — lowering Q1 2026 to about ($0.42) (from $0.05), Q2 to ~($0.17) (from $0.09), Q3 to ~($0.07) (from $0.18), and cutting Q4/QFY and FY2027–FY2029 targets (e.g., FY2027 to $2.33 from $2.90, FY2028 to $3.10 from $4.26, FY2029 to $4.68 from $5.87). These downward revisions increase short-term earnings uncertainty and weigh on fundamental expectations.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.